Human IP6K1 activation kit by CRISPRa

CAT#: GA106606

IP6K1 CRISPRa kit - CRISPR gene activation of human inositol hexakisphosphate kinase 1



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
Rabbit Polyclonal antibody to IP6K1 (inositol hexakisphosphate kinase 1)
    • 100 ul

CNY 6,281.00


Lenti ORF particles, IP6K1 (mGFP-tagged) - Human inositol hexakisphosphate kinase 1 (IP6K1), transcript variant 2, 200ul, >10^7 TU/mL
    • 200 ul

CNY 9,120.00


IP6K1 Rabbit polyclonal Antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol IP6K1
Locus ID 9807
Kit Components

GA106606G1, IP6K1 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA106606G2, IP6K1 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA106606G3, IP6K1 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_001006115, NM_001242829, NM_153273
Synonyms IHPK1; PiUS
Summary This gene encodes a member of the inositol phosphokinase family. The encoded protein may be responsible for the conversion of inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). It may also convert 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jun 2011]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...